In a remarkable breakthrough that challenges long-standing assumptions in cancer biology, researchers at Georgetown University’s Lombardi Comprehensive Cancer Center have unveiled an unprecedented dual role for the protein ezrin, a molecule deeply implicated in cancer metastasis. This discovery not only reshapes our understanding of ezrin’s function but also illuminates new potential therapeutic strategies, particularly in combating osteosarcoma, the most common form of bone cancer affecting children and young adults globally.
For many years, scientists have held that ezrin operates primarily in its open conformation at the cell membrane, where it plays a role in cellular structure and signaling. Its closed conformation, predominantly residing within the cell’s interior, was widely regarded as an inactive or dormant state with little functional relevance. However, this new study radically contradicts that paradigm, demonstrating that the closed form of ezrin is far from inert; rather, it actively engages in RNA binding activities crucial for sustaining metastatic cancer cell behaviors.
This groundbreaking work, published in the prestigious journal Science Signaling on March 17, 2026, was led by Dr. Aykut Üren, whose dual appointments in the Departments of Oncology and Biochemistry and Molecular & Cellular Biology underscore the cross-disciplinary nature of this research. Dr. Üren emphasizes that this revelation is a testament to how fundamental scientific inquiry can translate into practical clinical advances, particularly in addressing the lethal progression of metastatic osteosarcoma.
Osteosarcoma remains a significant clinical challenge, with approximately 1,000 new cases yearly in the United States alone. Half of these cases occur in pediatric and adolescent populations. While early detection can yield five-year survival rates between 60% and 75%, metastasis drastically diminishes survival odds to single-digit percentages. Therefore, understanding the molecular drivers that enable osteosarcoma cells to spread is critical to developing more effective interventions.
One of the study’s most innovative aspects involved modeling metastasis using zebrafish, a vertebrate model with transparent embryos that allows real-time visualization of cancer progression. To dissect ezrin’s dual conformations, the team engineered osteosarcoma cell lines entirely lacking ezrin protein, then reintroduced mutant variants that locked ezrin strictly into either its open or closed state. This elegant approach permitted the isolation of each conformational form’s distinct biological functions without the confounding presence of the other.
Their experiments revealed that the closed, unphosphorylated form of ezrin exhibits a heretofore undescribed capacity to bind directly to RNA molecules within cancer cells. This interaction modulates post-transcriptional gene regulation, specifically influencing the translation of RNA into proteins that promote cellular proliferation and metastatic competence. In essence, closed ezrin acts as an essential RNA-binding protein facilitating the aggressive dissemination characteristic of osteosarcoma.
Perhaps most strikingly from a therapeutic standpoint was the finding that closed ezrin alone could restore the metastatic properties to osteosarcoma cells previously deprived of all ezrin. This demonstrates that targeting ezrin’s open form alone, as previous strategies have attempted, may be insufficient due to the robust RNA-centric functions of its closed counterpart. These insights help explain the stubborn resistance of ezrin-dependent cancers to conventional interventions and invite new avenues for drug development.
Dr. Üren elaborates that the discovery of closed ezrin’s RNA-binding activity represents a profound shift in conceptualizing metastasis biology. The team’s work not only reveals the intricacies of ezrin’s conformation-dependent functions but also positions RNA interactions as an unexpected but crucial mechanism enabling cancer cell motility and survival during metastasis.
Building upon these findings, the research group has identified small molecules capable of inhibiting both open and closed ezrin forms. Early laboratory and murine model studies report promising results in suppressing osteosarcoma progression. Yet, as Dr. Üren candidly notes, optimizing these compounds for improved bioavailability and pharmacologic properties remains a critical hurdle before human clinical trials can be envisaged.
The translational potential of this research is substantial. By developing agents that disrupt ezrin’s interaction with RNA, it may become possible to arrest or even prevent the metastatic spread of osteosarcoma cells, thereby significantly improving patient outcomes. Given that ezrin is implicated in various other malignancies, these interventions could herald a new class of anti-metastatic therapies with broad applications.
This study exemplifies the power of combining genetic engineering, advanced molecular biology techniques, and in vivo models to unravel complex cancer mechanisms. The team’s interdisciplinary expertise enabled them to challenge entrenched dogmas and unveil a sophisticated layer of gene regulation orchestrated by ezrin’s structural dynamics.
Beyond osteosarcoma, the implications of ezrin’s RNA-binding activity resonate across multiple cancer types, suggesting a universal mechanism tumor cells exploit to metastasize. Continued investigation into ezrin’s interactome—especially which specific RNAs it binds and how this influences the metastatic cascade—will deepen our molecular understanding and refine therapeutic targets.
The research was conducted with no reported personal financial conflicts of interest among authors, reinforcing the study’s integrity. Funding was generously provided by the Children’s Cancer Foundation in Baltimore, underscoring the critical role of philanthropic support in pioneering cancer research.
This seminal work stands as a beacon of hope for patients facing metastatic osteosarcoma, highlighting how cutting-edge molecular discoveries can pave the way for life-saving treatments. As the scientific community eagerly anticipates the next stages of drug development and preclinical evaluation, this study sets a new paradigm for investigating and targeting the molecular underpinnings of cancer metastasis.
Subject of Research: Animals
Article Title: The unphosphorylated, closed form of ezrin binds to RNA to maintain a metastatic phenotype in osteosarcoma cells
News Publication Date: 17-Mar-2026
Web References:
http://dx.doi.org/10.1126/scisignal.ady8367
Keywords: Ezrin, Osteosarcoma, Metastasis, RNA-binding protein, Cancer biology, Molecular oncology, Zebrafish model, Translation regulation, Therapeutic targets
Tags: biochemistry of cancer metastasiscancer metastasis molecular mechanismschildhood bone cancer researchezrin closed conformation activityezrin in bone cancer metastasisezrin protein cancer signalingmolecular oncology in bone cancerosteosarcoma protein functionpediatric osteosarcoma treatment strategiesprotein ezrin dual roleRNA binding in cancer cellstherapeutic targets for osteosarcoma
